Medical Affairs & MSL Outsourcing: Build vs Buy for Pharma Launch Teams
Build vs buy framework for pharma medical affairs and MSL deployment. Cost benchmarks, vendor comparison across Inizio, Syneos, Indegene, EVERSANA, Lumanity, and Red Nucleus.
Curated by Rx Almanac using company materials, public reporting, and editorial synthesis.
On this page
Save this comparison — email yourself the full breakdown.
Join 200+ biotech launch teams on the weekly digest.
TL;DR
Medical Affairs (MA) is the non-promotional scientific function covering MSL field deployment, medical information, publications, scientific communications, HEOR, KOL engagement, and advisory boards. For a mid-size specialty launch, MA can be a material share of commercial opex, with the MSL field team often the largest controllable line item.
Outsourcing options range from full MA function outsource (EVERSANA Medical Affairs, Inizio Medical, Red Nucleus, Lumanity) to narrow MSL-only deployment (Inizio Engage, Syneos Health, Indegene) to specialist firms for publications, medical information, HEOR, and advisory boards. Boutique scientific firms typically bill on day-rate or project-retainer models, while full MSL deployment often prices above salary-plus-burden internal cost. The decision hinges on timeline to launch, therapeutic area depth required, pipeline size, and whether the manufacturer is a single-asset company or a multi-launch platform. Launch teams under 12 months out should outsource the field medical team by default; 24+ months out with committed pipeline, build.
Medical Affairs Function Scope
Medical Affairs sits under the Chief Medical Officer and operates under separate compliance rules from the commercial organization. Six functions account for nearly all MA spend.
Medical Science Liaisons (MSLs)
Field-deployed scientific professionals holding PhD, PharmD, or MD credentials. MSLs conduct peer-to-peer scientific exchange with KOLs, respond to unsolicited medical inquiries (including off-label in reactive mode), support investigator-initiated studies, gather clinical insights, and execute speaker training. MSLs are not promotional: they do not carry sales messages, are not compensated on prescribing volume, and are prohibited from coordinating call plans with sales reps.
Medical Information
Call centers handling unsolicited clinical and safety inquiries from HCPs, patients, and occasionally payers. Standard response infrastructure includes a toll-free line, email intake, response letter library, adverse event capture, and triage to in-house medical officers for novel questions. Medical information is the one compliant channel for reactive off-label data discussion.
Publications
Manuscripts, congress abstracts, posters, oral presentations, and congress materials. Publication planning sequences clinical evidence across high-impact journals and conferences to support regulatory milestones, payer HTA submissions, and launch readiness. Complex manuscript lifecycles are usually outsourced to a publications agency under project pricing.
Scientific Communications
Platform documents, slide decks, Lexicon-Based Library (LBL) content, MSL training materials, disease-state reference kits, and scientific narrative development. This function anchors the scientific story that flows through every other MA activity.
HEOR and Outcomes Research
Health economics and outcomes research teams build pharmacoeconomic models, budget impact analyses, AMCP dossiers, and generate real-world evidence to support payer decisions and HTA submissions. Scope overlaps with market access consulting and RWE vendors. A single major HEOR model or RWE study can become a large workstream depending on data sourcing, analytic complexity, and publication strategy.
KOL Engagement and Advisory Boards
Systematic identification, tiering, and management of Tier 1-3 KOLs (see market access consulting guide for the broader payer and provider mapping framework). Advisory boards commonly involve 10-20 attendees with fair-market-value honoraria. Major launches manage multiple advisory boards annually plus active investigator-initiated study pipelines.
Cost Structure
MSL Field Force
A fully loaded MSL cost model should include:
| Component | Cost Driver |
|---|---|
| Base salary (PharmD, PhD, or MD) | Seniority, therapeutic area, geography |
| Incentive compensation | Medical objectives and company pay philosophy |
| Benefits, payroll tax, retirement | Employer burden rate |
| Car program, travel, and expenses | Territory size and congress cadence |
| KOL meeting and advisory board budget | Scientific plan and KOL density |
| Training, congress attendance, technology | Launch complexity and platform stack |
| Regional/national manager overhead allocation | Span of control and governance model |
Therapeutic area dictates team size. Benchmark FTE counts for a specialty launch at steady state:
| Therapeutic Area | MSL FTE Count |
|---|---|
| Rare disease (single orphan indication) | 8-25 |
| Oncology (single tumor type or broad franchise) | 20-80 |
| Autoimmune and immunology | 30-100 |
| Primary-care-specialty (cardiometabolic, CNS) | 40-150 |
Oncology franchises with multiple tumor types or combination regimens push toward the higher end because each indication requires dedicated scientific capacity. Rare disease teams are smaller but more specialized, often fielding only one MSL per territory who covers the entire national KOL set for an ultra-orphan therapy.
Medical Information
In-house medical information operations require dedicated staff, technology licensing, response-letter content development, quality processes, and safety handoffs. Outsourced medical information through EVERSANA MedInfo, Inizio MedInfo, IPG Health/Klick, or IQVIA usually combines a base platform or staffing fee with transaction-based pricing. Transaction-based pricing aligns cost to volume and is economical for products with lower inquiry volume.
Publications
A single manuscript lifecycle includes manuscript development, statistical review, submission, reviewer response, and through-publication coordination. A typical launch publication plan covers pivotal trial analyses, sub-analyses, real-world evidence, and health economics, which can make publications a multi-year budget rather than a one-off writing project.
HEOR and RWE Studies
Major studies range from modest burden-of-illness analyses to comprehensive indirect treatment comparisons, pharmacoeconomic models, and multi-country RWE programs. Budget impact models and AMCP dossiers should be scoped as separate workstreams rather than bundled into generic medical communications retainers.
Full MA Function Benchmark
A mid-size biotech with one marketed specialty product can spend tens of millions annually on total medical affairs when counting MSL field force, publications, investigator-initiated studies, advisory boards, medical information, and HEOR/RWE. Large-pharma oncology or immunology franchises can spend substantially more because each indication requires dedicated field medical, evidence, and scientific-communications capacity.
Outsourcing Models
Four distinct outsourcing models serve different needs. Most manufacturers use a blend.
Full MA Function Outsource
Rare at scale, but common for pre-launch biotechs with no in-house MA infrastructure or for single-asset companies that want variable-cost MA through the commercial ramp. The vendor provides MSL deployment, medical information, publications, and scientific communications as an integrated offering.
Lead vendors: EVERSANA Medical Affairs, Inizio Medical (part of Inizio Engage), Red Nucleus, Lumanity.
Typical engagement: multi-million-dollar annual run rate for a single-asset launch, 24-36 month commitment, with build-operate-transfer options allowing the manufacturer to internalize the team at year two or three.
MSL-Only Deployment
The most common outsourcing model. The vendor deploys a contract MSL team under the manufacturer’s brand strategy and compliance oversight, with the vendor handling recruitment, training, certification, HR, and back-office. The MSLs function identically to in-house MSLs on a day-to-day basis.
Lead vendors: Inizio Engage (Medical Engagement), Syneos Health Medical Affairs (now part of the Syneos-Inizio combined entity), Publicis Medical (Publicis Health division), Indegene.
Typical engagement: 15-60 MSLs for 18-36 months, priced above salary-plus-burden internal cost, with 90-180 day ramp and an option to convert contract MSLs to internal hires at the end of the term.
Scientific Communications and Publications
Specialist agencies that handle publication planning, manuscript development, congress materials, advisory board content, and MSL training materials. These firms rarely deploy field personnel.
Lead vendors: Red Nucleus, Open Health Communications, Lumanity (formerly Cello Health communications teams), Nucleus Global (part of Inizio), Caudex (part of IPG Health).
Typical pricing: day-rate or project-retainer pricing; annual retainers for a full publication plan; separate work orders for complex manuscript lifecycles.
Medical Information Call Centers
Outsourced medical inquiry response is a mature market. The vendor provides the technology platform, trained respondents, response letter library, adverse event capture workflow, and regulatory reporting.
Lead vendors: EVERSANA MedInfo, Inizio MedInfo, IPG Health (including Klick Health’s medical information operations, see Klick Health), IQVIA Medical Information, Indegene Medical Information.
Typical pricing: annual base platform or staffing fee for a specialty product plus per-inquiry fees depending on complexity.
Advisory Boards, KOL Mapping, and HEOR
These tend to be purchased as discrete studies or engagements rather than ongoing retainers.
Lead vendors: Trinity Life Sciences, Lumanity, Precision AQ, Cello Health (now part of Lumanity), IQVIA Medical, Open Health.
Typical pricing: project pricing by scope for advisory board execution, KOL mapping and tiering, major HEOR models, and RWE studies.
Head-to-Head Vendor Comparison
| Vendor | Scope | Min Engagement Size | Typical Pricing | Differentiator |
|---|---|---|---|---|
| EVERSANA Medical Affairs | Full MA stack (MSL + MedInfo + Pubs + HEOR) | ~$5M annual | Blended FTE + project | Only vendor with fully integrated MA-plus-commercial-plus-hub platform; useful for biotechs outsourcing the entire commercial stack |
| Inizio Engage (Medical) | MSL deployment, medical information, medical education | 10-15 MSL minimum | 115-125% of loaded in-house cost | Largest global contract MSL operator post-Syneos combination; strong in US and EU simultaneous deployment |
| Syneos Health Medical Affairs | MSL, medical information, publications | 8-12 MSL minimum | 115-125% of loaded in-house cost | CRO integration allows clinical-to-commercial continuity for biotechs running Phase III with Syneos |
| Indegene | MSL deployment, medical information, medical digital | 8-15 MSL minimum | 105-115% of loaded in-house cost (lower via offshore support layer) | Digital-first model with India-based analytics, content, and medical information back-office. Lowest cost point of the MSL-deployment vendors |
| Red Nucleus | Publications, scientific communications, MSL training, medical education | $500K project minimum | $2-4K/day consultant rates; $150-500K per manuscript | Deep medical education heritage; strongest in launch training and congress execution |
| Lumanity | HEOR, value communication, medical strategy, publications | $300K project minimum | $3-5K/day consultant rates | HEOR-anchored value demonstration; strong HTA submission track record including NICE, ICER, and EU Joint Clinical Assessment |
| Open Health | Publications, HEOR, market access evidence, KOL engagement | $250K project minimum | $2-4K/day consultant rates | Works with 49 of top 50 pharma; strongest independent communications shop |
| Trinity Life Sciences | KOL mapping, advisory boards, medical strategy | $200K project minimum | $3-5K/day consultant rates | US-focused commercialization consultancy; strong on payer-medical integration |
| Precision AQ | Medical strategy, HEOR, publications | $300K project minimum | $3-5K/day consultant rates | 1,200+ market access and HEOR experts; Access Experience Team of former payer decision-makers |
| IQVIA Medical | MedInfo, KOL data (ProfScience), MSL territory analytics | $100K project minimum | Data platform subscriptions plus project fees | Only vendor with integrated MSL territory optimization driven by prescribing and claims data |
| Klick Health | Medical information, medical digital, KOL analytics | $200K project minimum | Project-based | Data-driven KOL mapping; strong digital medical affairs infrastructure |
Most manufacturers use a primary MSL vendor plus two to four specialist firms: a publications agency, a MedInfo vendor, an HEOR consultancy, and a medical education shop. Consolidating everything with one vendor simplifies governance but reduces leverage and specialization.
Build vs Buy Decision Framework
Six factors drive the build-vs-outsource decision.
1. Timeline to Launch
| Timeline to Launch | Recommended Model |
|---|---|
| Less than 12 months | Outsource MSL deployment. Internal hiring and training cannot close the gap. |
| 12-24 months | Hybrid. Build the core team (medical lead, 2-4 senior MSLs, publications lead) and outsource the field MSL ramp. Convert contract MSLs to internal at month 18-24. |
| 24+ months | Build if budget allows. Full internal team is economical at 3+ year horizon and builds institutional scientific capability. |
Hiring a single experienced MSL takes 90-150 days. Building a 30-MSL team from zero internally is an 18-24 month exercise even with a fully resourced talent acquisition team. Timelines shorter than 12 months to launch have no realistic build option.
2. Therapeutic Area Depth
Deep specialty areas (cell and gene therapy, rare oncology indications, neurological diseases with complex endpoints) reward building. The scientific dialogue requires institutional knowledge that accumulates in-house over years. Contract MSLs can be excellent, but the best scientific capabilities (deep mechanism expertise, trial-history memory, KOL relationships across indications) are hard to rent.
Broader specialty areas with well-characterized mechanisms (many autoimmune indications, most cardiometabolic launches) are more amenable to contract MSL deployment because the scientific baseline is well understood across the field.
3. Pipeline Size
A single-asset biotech has no economies of scale for a dedicated in-house team. Fixed costs (medical leadership, infrastructure, training programs, compliance systems) get spread over one product. Outsourcing is typically the right call.
A platform company with 3+ marketed products and 5+ Phase II/III assets has enough scale to justify a full in-house MA infrastructure, including MSL management, publications, medical information, and HEOR.
4. Uncertainty of Commercial Trajectory
Biotechs facing binary Phase III readouts or pre-approval regulatory risk should avoid fixed in-house commitments. A contract MSL team can be scaled down in 60-90 days if clinical data disappoints; a 40-person in-house team cannot, and severance plus morale damage are material.
5. Geographic Complexity
Simultaneous US and EU5 launches, or US plus Japan, benefit from contract vendors that already have trained MSLs and compliance infrastructure in multiple geographies. Inizio Engage and Indegene have particular depth in cross-geography deployment. Building internal infrastructure in five countries for a launch is rarely economical.
6. Scientific Differentiation Strategy
For a first-in-class therapy where scientific positioning is the entire commercial story (for example, a novel mechanism cell therapy in oncology), the case for building is strongest. The in-house team becomes part of the scientific identity of the company. For a fast-follower or biosimilar launch, contract deployment is sufficient.
Commercial Buyer Pitfalls
Six errors show up repeatedly in post-launch retrospectives.
1. Treating MSLs Like Sales Reps
The most common and most serious error. MSLs sitting in commercial staff meetings, carrying sales-message talking points, being compensated on prescribing volume in their territory, or coordinating account plans with commercial reps all create PhRMA Code and FDA promotional-compliance exposure. Several recent DOJ settlements and corporate integrity agreements trace back to exactly this blurring. The fix is structural: MSLs must report through the medical organization to the CMO, must be compensated on non-commercial metrics (insights gathered, IIS proposals supported, KOL engagement quality), and cannot share call plans or target lists with commercial.
2. Under-Investing in Medical Information for Rare or Complex Drugs
For a rare disease or cell/gene therapy launch, medical information is not a call-center commodity. It is the primary channel through which community HCPs get unstuck on dosing, administration, safety management, and adverse event handling. Under-investing here produces slow HCP response, abandonment of treatment initiation, and reputational damage. Staff a senior medical officer for clinical escalation, not a generalist call center.
3. Outsourcing HEOR Without a Strategic Framework
HEOR studies tend to be commissioned one at a time as payer submissions approach. This produces a portfolio of disconnected studies that payers find underwhelming and that HTA bodies challenge. The fix is an integrated evidence generation plan (typically authored with Lumanity, Precision AQ, or Trinity Life Sciences) that sequences RWE, indirect treatment comparisons, and budget impact models against specific payer decision points. See the market access consulting guide for vendor selection in that adjacent function.
4. Publications as an Afterthought
A publication plan developed at launch minus 6 months will not land a manuscript in a top-tier journal in time for the launch window. Good publication planning starts in Phase II with a 36-month forward plan mapped to regulatory milestones and key congresses. Late-stage publication planning is reactive and produces weaker evidence packages.
5. Conflating Contract MSL Cost Premium with Inefficiency
The 15-25% premium over fully loaded internal cost is not waste. It is payment for speed to deployment, variable commitment, elimination of severance risk, and pre-existing compliance and training infrastructure. For a biotech with binary launch outcomes, the option value is worth the premium. The correct comparison is not contract-MSL cost vs. idealized in-house cost; it is contract-MSL cost vs. in-house cost plus the risk-adjusted downside of a failed launch with fixed personnel obligations.
6. Failing to Plan the Contract-to-Internal Conversion
Manufacturers that intend to internalize contract MSLs at year two often fail to negotiate clear conversion rights upfront. The best vendors (Inizio, Syneos, Indegene) allow conversion at a defined per-MSL fee ($15-30K). Weak contracts either prohibit conversion outright or charge full annual fees. Negotiate this at contract signing.
Operating Model Integration
Medical affairs does not operate in isolation. Three integration points matter most.
MSL and FRM Coordination
Field Reimbursement Managers (FRMs) sit within market access and handle access, coverage, and reimbursement questions from HCP offices. MSLs handle scientific inquiries. The two teams cover overlapping HCP targets but under different PhRMA Code provisions. Clear boundaries matter: FRMs cannot discuss clinical data beyond approved label; MSLs cannot discuss formulary negotiations or contract pricing.
The best-run launches have explicit field playbooks clarifying which team leads each HCP touchpoint, with handoff protocols when a scientific conversation surfaces an access question or vice versa. See pharma services explained: hub, specialty pharmacy, and FRM for the broader field-force context.
MSL and Market Access Evidence Strategy
HEOR models, RWE studies, and indirect treatment comparisons live inside medical affairs, but payer access decisions happen inside market access. An integrated evidence strategy aligns MA evidence generation with payer decision windows. Launches that treat these as separate budgets produce evidence packages that do not answer the questions payers actually ask.
Medical Information and Hub Triage
The hub handles access and reimbursement patient inquiries; medical information handles clinical inquiries. The triage protocol determines how fast patients get answers to the right team. Hub inbound calls with a clinical safety question must route to medical information within minutes, not hours. Product launches that use the same vendor for both hub and medical information (EVERSANA, Inizio) get cleaner triage by default; launches with separate vendors must build explicit routing logic.
Technology and Infrastructure
Veeva Vault MedComms and Veeva Vault Medical CRM have become the de facto standard for in-house medical affairs operations. Veeva Systems dominance in MA mirrors its dominance in commercial CRM, creating a single vendor dependency across the medical-commercial divide. Alternatives (IQVIA Orchestrated Customer Engagement, Medidata, various niche MSL CRMs) have struggled to take share at the large-pharma tier, though mid-size biotechs still evaluate competitors.
Outsourced MSL vendors typically deploy on their own platforms during the contract period, with a data transition at conversion. Verify upfront that MSL interaction data, KOL relationship records, and medical inquiries transfer cleanly to the manufacturer’s platform at contract end.
Launch-Ready Quick Reference
| Decision | Default Answer |
|---|---|
| Timeline under 12 months | Outsource MSL deployment |
| Single asset, pre-approval | Outsource or hybrid |
| Platform company, 3+ assets | Build |
| Rare disease or cell/gene | Build or long-term partnership with specialist |
| Medical information for specialty launch | Outsource unless inquiry volume exceeds 5,000/year |
| Publications for launch | Outsource to specialist; in-house planning lead |
| HEOR models | Specialist outsource (Lumanity, Precision AQ, Trinity) with in-house strategic lead |
| Advisory boards | Outsource logistics and content development |
| KOL mapping | Outsource to data-first vendor (IQVIA, Klick, Trinity) |
| Simultaneous US/EU launch | Outsource or hybrid with cross-geography vendor |
Related Reading
- Market Access Consulting: Trinity vs IQVIA vs Guidehouse vs Precision AQ vs Lumanity for payer-side evidence and pricing strategy
- Rare Disease Launch Vendor Playbook for ultra-orphan launch MA team design
- Oncology Launch Vendor Playbook for tumor-type-specific MSL deployment sizing
- Pharma Services Explained: Hub, Specialty Pharmacy, and FRM for field-force role clarity across medical, commercial, and access
- Hub Services Buyer’s Guide for medical information and hub triage integration
Rx Almanac maintains a private source register for each article. Material public claims are cited inline; sourcing standards and correction policy are described in our methodology.
Frequently Asked Questions
How much does an outsourced MSL cost compared to building in-house?
A fully loaded in-house MSL is best modeled as base salary plus incentive, benefits, travel, KOL engagement budget, training, technology, and management overhead. Contract MSLs from firms such as Inizio Engage, Syneos Health, or Indegene often price above salary-plus-burden internal cost in exchange for speed to deployment, variable commitment length, and lower severance risk. For single-asset biotechs with uncertain commercial trajectories, the premium is usually worth it. For platform companies building a multi-asset franchise, in-house becomes more economical after the launch-risk window.
Can you outsource the entire medical affairs function or just MSLs?
Both models exist. Full medical affairs outsourcing (MSL plus medical information plus publications plus HEOR plus scientific communications) is offered by EVERSANA Medical Affairs, Inizio Medical, Red Nucleus, and Lumanity, typically at a multi-million-dollar annual run rate for a single-asset launch. MSL-only deployment is the more common model, supported by Inizio Engage, Syneos Health Medical Affairs, Publicis Medical, and Indegene. Narrow scope outsourcing is also common: medical information call centers, publications planning, or HEOR studies can each be sourced from specialist firms without touching the rest of the function.
Is using an MSL as a sales rep a compliance violation?
Treating an MSL as a promotional extension of the sales force is one of the highest-risk errors in pharma commercial operations. The PhRMA Code and FDA guidance draw a clear line between non-promotional scientific exchange (the MSL role) and promotional activity (the sales rep role). MSLs can discuss off-label data reactively in response to unsolicited HCP questions; sales reps cannot. MSLs must report to the Chief Medical Officer or equivalent scientific/medical leader, not commercial. Violations (for example, MSLs carrying sales messages, being compensated on prescription volume, or coordinating call targeting with commercial) create the same promotional-compliance and inducement risk pattern that has driven DOJ settlements and corporate integrity agreements in pharma. Outsourced MSLs do not change this risk; the manufacturer remains accountable for how the field team operates.
When does a biotech need MSLs and when can it defer?
MSLs should be field-deployed 9-12 months before launch for specialty products and 12-18 months before launch for rare disease, cell and gene therapy, or first-in-class therapies where scientific education drives adoption. Deferral is reasonable only when the drug is broadly familiar (a biosimilar or a me-too in a mature class), the KOL universe is small enough to cover from headquarters, or the company has an existing medical team with capacity. Every other launch profile, especially oncology, rare disease, immunology, and neuroscience, needs field medical on the ground before the first promotional touch, because the scientific dialogue starts with KOLs who want to understand mechanism, trial data, and safety long before they receive a sales call.
Related Articles
Analysis
340B TPA Comparison: Apexus vs Sentry Data Systems vs Macro Helix
Covered-entity 340B TPA comparison for Apexus, Sentry Data Systems, and Macro Helix, with manufacturer channel-risk implications.
Analysis
Cell and Gene Therapy Services Comparison: Orsini vs PANTHERx vs Onco360 vs Accredo vs CVS
This comparison supports a manufacturer-side CGT launch decision: which specialty-pharmacy and access partner can handle product-specific requirements around cryogenic handling, REMS, treatment-center coordination, payer access, hub orchestration, and long-term follow-up.
Analysis
Field Force Outsourcing Comparison: Syneos vs EVERSANA vs Trinity vs Inizio vs Amplity
This analysis supports a manufacturer decision on outsourced field teams, field reimbursement managers, medical science liaisons, nurse educators, and adjacent commercialization operations.
Get more analysis like this
Weekly pharma vendor intel: new comparisons, market updates, and expert insights.
Found an inaccuracy? Tell us.
Suggest a correction